People with Lou Gehrig disease are living longer

	Tweet

Compared to years past, people who come down with Lou Gehrig disease nowadays seem to have slower disease progression and to live long. Nonetheless, amyotrophic lateral sclerosis or ALS, as the disease is known formally, is still always fatal, ultimately.

Baylor University researchers, reporting in the Archives of Neurology, have not found any specific factor to account for the improvements in recent years.

Dr. Adam Czaplinski and colleagues in Houston, Texas analyzed survival time and disease progression in two groups: 647 patients diagnosed with ALS between 1984 and 1999, and 394 patients diagnosed between 1999 and 2004.

The average survival after symptom onset was 3.22 years for patients in the first group compared with 4.32 years for patients in the more recent group.

Time to “a clinically evident change in a patient’s clinical status and ability to perform activities of daily living” was 10 months in the current era compared with 9 months in ALS patients treated in earlier years.

The researchers observe that the improvement in outcome could not be attributed to any particular ALS-specific treatment, but they say they cannot rule out an effect of concurrent illnesses, “which could have influenced medical treatment and survival.”

The researchers conclude that that there are other possible interpretations of the findings, including the possibility that there has been “a fundamental change in the natural history of the disease.”

SOURCE: Archives of Neurology, August 2006.

RELATED STORIES:
How Lipitor Helps Alzheimer’s Disease   Violent video games alter brain function in young men   Newly discovered role for enzyme in neurodegenerative diseases   Genetic Clues to Rare Childhood Disorder   Research provides clues to neurodevelopemental disorders   Neurological disease common, survey finds   Gene that increases risk for Alzheimer’s disease   More exercise equals lower risk of ischemic stroke   X-ray eyes bring us closer to early diagnosis of Parkinson’s disease   “Preconditioning” Helps Protect Brain’s Blood Vessels from Stroke   Possible target for future therapies aimed at delaying or stopping Alzheimer’s disease   Thalidomide may slow Lou Gehrig’s disease

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]